Patients at high risk of invasive fungal infections: when and how to treat.
about
Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatusSensitivity of clinical isolates of Candida to essential oils from Burseraceae familyTriazole Resistance in Aspergillus Species: An Emerging Problem.Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation.MALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi.Formulation and candidacidal activity of magnetic nanoparticles coated with cathelicidin LL-37 and ceragenin CSA-13.Evaluation of lysine biosynthesis as an antifungal drug target: biochemical characterization of Aspergillus fumigatus homocitrate synthase and virulence studiesAdvances in the treatment of neutropenia.Management of febrile neutropenia: ESMO Clinical Practice Guidelines.Fungi are Not All "Fun-Guys" after All.Pharmacoeconomic evaluation of voriconazole vs. liposomal amphotericin B in empiric treatment of invasive fungal infections in Turkey.Novel strategies to fight Candida species infection.Candida colonization index in patients admitted to an ICU.Candida albicans infections in renal transplant recipients: effect of caspofungin on polymorphonuclear cellsDiagnosis of invasive aspergillosis by a commercial real-time PCR assay for Aspergillus DNA in bronchoalveolar lavage fluid samples from high-risk patients compared to a galactomannan enzyme immunoassay.Evaluation of gene expression SAP5, LIP9, and PLB2 of Candida albicans biofilms after photodynamic inactivation.Antifungal management and resource use in patients with acute myeloid leukaemia after chemotherapy--retrospective analysis of changes over 3 yr in a German hospital.High-Resolution SNP/CGH Microarrays Reveal the Accumulation of Loss of Heterozygosity in Commonly Used Candida albicans StrainsCaspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry.Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in CanadaVariation in Candida albicans EFG1 expression enables host-dependent changes in colonizing fungal populations.Normal adaptation of Candida albicans to the murine gastrointestinal tract requires Efg1p-dependent regulation of metabolic and host defense genes.Invasive fungal infections in acute leukemia.Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question?Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerationsPosaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts.Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy.The strategy of antibiotic use in critically ill neutropenic patientsEconomic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies.Acute leukaemia: making sense of a complex blood cancer.A practical critique of antifungal treatment guidelines for haemato-oncologists.Complement Attack against Aspergillus and Corresponding Evasion Mechanisms.Diagnosis and treatment of invasive fungal infections focus on liposomal amphotericin B.Echinocandins: production and applications.Pharmacoeconomics of empirical antifungal use in febrile neutropenic hematological malignancy and hematopoietic stem cell transplant patients.Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective reviewNeurological complications of transplantation: part I: hematopoietic cell transplantation.Our 2014 approach to candidaemia.Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.
P2860
Q28752041-60DB23D3-109C-4F6F-B908-0CE157741695Q28830247-D76DDC28-949D-4AF8-8B4C-C0412B5F3DFAQ30235566-ABD0E244-5594-433F-9464-15A8DC5B8E01Q31170227-24FFDD23-BA87-4ABE-8710-6587818703C4Q33725726-0CCC7DC3-9F67-4C9E-A357-A1A0EAF9E33AQ33870762-F87FF0BD-BECC-4F10-9D01-B1677894571FQ33983108-4E650FC8-5CD6-4B31-A6FF-3FF2956FE5A6Q34609244-B1B671A2-2998-4D02-9C74-97585F93D48BQ34620670-D672AD04-349A-4AC4-A613-247AAB91C996Q35029633-09C2ACD1-C235-43E5-AF62-E6D08769F694Q35054434-766D22BF-9C15-49E8-83C6-28029F843F97Q35406737-F3788E5F-4232-4C26-834D-46ADA32B9533Q35536078-A351644F-B465-4D46-8B3C-5F923D59F4E2Q35598563-3523EC38-5245-48B3-AE55-E684232AB8ABQ35599066-709EB972-C822-491B-B51B-3CA9F5408F2DQ35616063-F988F3BA-FB86-4D3B-80BC-DF6CE0834151Q35700698-0CC01268-1F9E-40D0-A461-A7E48E6A0D8AQ35746841-970F8360-3F8B-44FE-8D66-7FB50CA82380Q35958060-D57F824B-ED8C-4818-9B29-CBA33C48F095Q36023082-49F3CCF4-C96B-46F2-883A-090C7BDD48FCQ36111766-3B2DFF57-8C50-4D6B-9440-06C0C9BC0CFAQ36145873-1FE94A66-2B09-4102-95B6-EB4532A53087Q36505103-801C81E4-704C-4052-8C1B-4F7E46B116FEQ36612597-90D04BE1-2EEA-4567-ACDE-9475D7C7DD69Q37657464-65A91E6F-097A-4A61-88F3-6BA09A04FF5EQ37740176-E3C86D29-938F-43C5-B113-5143494A0FA1Q37839071-58587311-547B-4BBE-AD1C-84BB7E7DF2D6Q37900678-E983D3FE-C000-47E2-890C-822512EAB740Q37929895-007A4F49-C03E-4600-A1A5-4BA60FA07143Q37936259-62A3DF6B-2C31-40A7-B8B4-C1C034BF7B1DQ37981504-5D5FF900-69B5-4ACC-A5D0-B0BED5A6D8D9Q37983106-DE85BD90-C15D-4BBC-B703-5F6704E62D31Q38038600-120D7012-7232-432D-80BC-3BEF77785FEEQ38079194-3A66D2F6-E254-46F7-A24F-B9AB160BC6A1Q38086769-A21871B2-598B-448F-9C90-ADCEAAF641B2Q38097528-446678B0-7059-4B44-8089-DF379063E61AQ38111391-52E57281-655A-4743-A6C0-4FCB42999EFFQ38132157-A0399BAE-0FE0-481D-AA87-846FBEE6407CQ38215111-5424BB39-5648-451C-8341-326F94DD259FQ38222029-2EB0CC71-7C89-4C18-8579-F195FDAA772B
P2860
Patients at high risk of invasive fungal infections: when and how to treat.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Patients at high risk of invasive fungal infections: when and how to treat.
@en
Patients at high risk of invasive fungal infections: when and how to treat.
@nl
type
label
Patients at high risk of invasive fungal infections: when and how to treat.
@en
Patients at high risk of invasive fungal infections: when and how to treat.
@nl
prefLabel
Patients at high risk of invasive fungal infections: when and how to treat.
@en
Patients at high risk of invasive fungal infections: when and how to treat.
@nl
P2093
P1433
P1476
Patients at high risk of invasive fungal infections: when and how to treat.
@en
P2093
Jörg J Vehreschild
Maria J G T Rüping
Oliver A Cornely
P304
P356
10.2165/00003495-200868140-00002
P577
2008-01-01T00:00:00Z
P5875
P6179
1052447643